ASCO 2024

Immunotherapy makes a difference in survival in eTNBC

The search for predicitve biomarkers continues

Prognostic value of ctDNA in therapeutic strategies; Endocrine therapy in ER-low BC

AI for the prediction of disease progression

Adjuvant endocrine therapy for ER-low EBC

Personalized neoadjuvant therapy for high-risk breast cancer patients

Avelumab in early TNBC

ctDNA analysis in monarchE

Advantage for node-negative patients

Ribociclib is also effective in N0 HR+/HER2− EBC

ctDNA important for HR+ eBC?

Avelumab nel TNBC precoce

Improvement for firstline treatment for patients with endocrine resistance

One step closer to chemo-free therapy for HR+/HER2+ patients

Reassuring and clarifying new data for CDK4/6 inhibitors

Expanding T-DxD use to HER2 ultra-low - the success story continues

Is there still a place for endocrine therapy in HER2+ BC

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

Leptomeningeal metastases in HER2+ mBC

Responder premenopausal

ER-low: endocrine therapy necessary after all?

Triple positive mBC - chemotherapy unnecessary?

Heterogenity of ER+ disease

New data on the omission of chemotherapy in young patients

Systemic therapy of HER2+ patients with brain metastases

Expanding use of T-DxD in HER2low and HER2 ultra-low MBC patients

Novel ADC-ICI combination therapy

Sacituzumab tirumotecan - a new powerful ADC for advanced TNBC

Broaden T-DXD as therapy standard for HER2low and ultra-low MBC

T-DXD continues its impressive track record for MBC patients

The ADC revolution continues - ctDNA takes the next step in tumor characterization

Decreasing SG related toxicity with profilatic G-CFS

HER2+ mBC 1stL T-Dxd

Ultra low - ultra good?

Important OS benefit with T-Dxd in HER2+ mBC

CDK4/6 rechallenge

Treatment beyond progression for CDK 4/6i

First-line inavolisib/placebo + palbociclib + fulvestrant preferred in patients with PIK3CA HR+ HER2- advanced breast cancer

Chemo-free, CDK4/6 inhibitor-based combination active in HR+/HER2+ PAM50-luminal advanced breast cancer

Endocrine therapy with Palbociclib + Trastuzumab

Chemo-free regimen in HER2+ luminal breast cancer

CDK4/6i effective in premenopausal patients as well

Already more in the 1stL?

INAVO120 - updated results

INAVO120: risultati aggiornati

Disminución de la toxicidad relacionada con la OS con G-CSF y loperamide profiláctica

Importante beneficio en la supervivencia global con TDxD en el CMm HER2+

Espansione dell'uso di T-DxD nelle pazienti con carcinoma mammario metastatico HER2-low e HER2 ultra-low

La révolution de l'ADC se poursuit / ctDNA franchit une nouvelle étape dans la caractérisation des tumeurs

Regime senza chemioterapia nel carcinoma mammario luminoso HER2+

CDK4/6 rechallenge

C'è ancora posto per la terapia endocrina nel BC HER2+?

Sacituzumab tirumotecan – nowy aktywny koniugat w leczeniu zaawansowanego raka trójujemnego

Le traitement endocrinien a-t-il encore sa place dans la CB HER2+ ?

Leczenie bez chemioterapii, oparte na inhibitorze CDK4/6 aktywne w zaawansowanych rakach HR+/HER2+ o fenotypie luminalnym wg PAM50

Is the metformin story over? How to treat HFNS symptomatology?

PSMA-PET CT: Ready for clinical practice or a PROMISE for the future?

Interesting data - but not practice changing

Focus on Quality of Life

RCT in mCRPC

Unveiling the Potential: PSMA-PET in Prostate Cancer Staging - Insights from the PROMISE TRIAL

EMBARK demonstrates the importance of HRQoL benefit in both combination and monotherapy arms

EMBARK: Quality of Life

mCRPC: Who benefits from which measures?

The evolving role of PSMA-PET with new agents

ARASENS Post hoc analysis: Therapy after progression

Exploring the CHAARTED TRIAL: Optimizing Treatment Strategies in Metastatic Prostate Cancer

Radionukleotides - the next step forward

Important QoL data

mCRCP CYCLONE 2 study

Deciphering EMBARK: Exploring Enzalutamide's Impact on Prostate Cancer Progression and Quality of Life

Unlocking Insights: The ALLIANCE Trial redefining Prognostic Models in Metastatic Prostate Cancer

Perioperative treamtent in MIBC - new data for the use of sacituzumab govitecan

EV-Pembro shows consistent outcome - caution with subset analyses

ctDNA as a biomarker in metastatic bladder cancer

Modified FOLFIRINOX therapy as a good option for urachus carcinoma

Effect of an immune diet on the outcome after radical cystectomy

Treatment of urachal carcinoma

What to do with Cis Gem Nivo?

ASCO 2024: Time for the rare GU tumors?

Preoperative use of sacituzumab govitecan

Biomarkers and long-term outcomes in pts with low tumor burden

Quality of life not affected by i. v. Pembro

MI-UC - News from EVP standard

ASCO24: Bladder cancer highlights

Interim analysis of the SURE-01/02 study

The Role of Topoisomerase Inhibitors in the preoperative setting of MIBC: The story has just begun

The future of sacituzumab govitecan

Biomarcadores y resultados a largo plazo en pacientes con baja carga tumoral

El futuro de sacituzumab govitecan

ASCO 2024: momento para los tumores GU poco frequentes?

El papel de los inhibidores de topoisomerasa en el contexto perioperatorio del cancer de vejiga musculo infiltrante: la historia acaba de empezar

ASCO24: Bladder cancer highlights

Supportive real-world data from German research platform CARAT

Evaluating risk criteria and monotherapy in mRCC

Advancing our understanding of biological mechanisms and the quest for the Ideal biomarker - Part 1

Advancing Our Understanding of Biological Mechanisms and the Quest for the Ideal Biomarker - Part 2

Combination is superior to monotherapy - how do we translate the results into clinical practice?

Another breakthrough perioperative

New IMDC risk group - very favorable

nccRCC

Belzutifan in earlier lines in advanced ccRCC

KIM-1 - old wine in new bottles

The search of the ideal biomarker in advanced renal cell carcinoma: The Sisyphus myth?

The never ending saga of biomarkers

Treatment of favorable prognosis mRCC patients: additional data to support treatment decisions

Metastasized chromophobe RCC

KIM-1: Will have a major impact

Combination therapies for chromophobe renal cell carcinoma are clearly superior

Biomarker analysis of KN426 & CLEAR

NIVO+CABO: significantly longer therapy-free time

Adjuvant KIM-1 as prognostic & predictive biomarker

New HIF inhibitor in clear cell RCC

DFF332 a novel HIF inhibitor

Tratamiento del cancer renal avanzado de pronostico favorable: datos adicionales para ayudar en la decision clinica

La busqueda del marcador ideal en el cancer renal avanzado: el mito de Sísifo?

Adjuvant therapy: how to identify patients who will benefit

End of the story in EGFRm disease?

Confirmed efficacy of periop IO in N2 R-NSCLC

Stadium III EGFR+: now permanently Osimertinib?!

4-year efficacy of Keynote-799 and ctDNA

Early change in SOC in EGFR+ LD-NSCLC

Osimertinib improves PFS in stage III

Perioperative chemotherapy and N2 status

ctDNA predicts outcome in patients treated with osimertinib

Gamechanger in EGFR-mutated NSCLC

CheckMate 816: 4-year update

Liquid biopsy in curative situation

4y follow-up of CheckMate 816

Cambio temprano en el tratamiento estándar del EGFR+ LD-NSCLC

Le traitement adjuvant par osimertinib apres CTRT : changement de donne dans le cas du CBNPC muté EGFR

4y follow-up de CheckMate 816

Lorlatinib with extraordinary data in ALK + NSCLC

Update for EGFR-positive NSCLC

TROP2-targeting ADCs: where a we heading?

KRAS in NSCLC - a lot to come

ADCs - moving landscapes. Subgroups remain to be defined.

BAY2927088 - Promising Her2-Inhibitor in NSCLC

Confirmed efficacy of adagrasib in KRASG12C

Lorlatinib convincing in ALK mutation 1st line

Confirmed efficacy in PD-L1 negativity - CheckMate 9LA

KRASG12C - the story continues

ASCO 2024 highlights

KRAS building on single agent therapy

EGFR+ NSCLC - amivantamab-based combination therapy

The end for local therapy for oligometastatic disease

Subcut amivantamab - the future

Adagrasib for KRASG12C mutation 2nd line

ALK+ NSCLC - CROWN revisited

Telehealth is just as effective as a face-to-face visit in early palliative care

Het einde van lokale therapie voor oligometastatische ziekte

La télésanté est aussi efficace qu'une consultation face a face dans les soins palliatifs précoces

KRASG12C - het verhaal gaat verder

ASCO 2024 highlights

BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC

ASCO 2024 highlights

Redefining SOC in LD-SCLC: Durvalumab as consolidation therapy

New SoC for LD-SCLC

Tarlatamab shows activity in patients with brain metastasis

Maintenance with durvalumab is the new SOC after chemo/radio therapy for LD-SCLC

Finally, change for LS-SCLC

LD-SCLC: What´s about PCI?

Le traitement d'entretien avec le durvalumab est le nouveau SOC après la chimio/radiothérapie pour le carcinomes à petites cellules en forme limitée

Tot slot, verandering voor LS-SCLC

Unexpected results; which subgroup could benefit from atezolizumab?

Harsh to beat

Chemo-immuno in mesothelioma - update

Difícil de superar

Personalized mRNA-vaccination: Practice changer of the future?

Stimulating new combination of two antibody-cytokine fusions

Is adjuvant treatment still standard in macroscopic, resectable stage III melanoma?

10 years follow up - immunotherapy for BRAF-mutated melanoma

Is the induction treatment the new strategy for selected patient group?

Is the triplet ready for phase 3?

Impactful studies from ASCO 24 III: Cell-therapy

Survival data for TT with dabrafenib and trametinib

TIL therapy for metastatic melanoma

Emerging rescue therapies for PD1 refractory melanoma

Promising Results: Triple combination therapy in advanced melanoma

3-year update on mRNA vaccines in melanoma

Intralesional therapy with Daromun

Impactful studies from ASCO 24 II: Combi-AD

Neoadjuvant immunotherapy treatment for melanoma

Promising activity of brenetafusp in PD-L1 refractory melanoma

Progress in neoadjuvant therapy with IO

Identifying patients with longterm benefits during tebentafusp in mUM

A new therapy benchmark for brain-met melanoma patients

mRNA vaccine plus pembrolizumab in adjuvant therapy

No differences in PFS between the two study arms

A new triplet for metastatic melanoma

Impactful studies from ASCO 24 I: NADINA

New oncolytic immunotherapy (RP1) after PD-1 failure

Longterm survival after adjuvant targeted therapy

Consolidation of the use of IO in clinically detectable stage III melanoma

Neoadjuvant intratumoral therapy with Daromun in metastatic melanoma

Adjuvant therapy with dabrafenib and trametinib - final results after 4 years

Lentigo maligna therapy

Triple checkpoint blockade - a new approach?

Vaccine in combination with nivolumab for PDL1 resistance

Consolidación del uso de IO en melanoma en estadio III clínicamente detectable

Prometedora actividad de brenetafusp en melanoma refractario a PD-L1

No hubo diferencias en la PFS entre los dos brazos del estudio

Risultati promettenti: Tripla terapia di combinazione nel melanoma avanzato

New therapeutic approaches: Get over PD1 resistances?

Encouraging developmental IO-options

New insights in localized HNSCC

New perspectives in HPV+ r/m HNSCC

New MOA in r/m HNSCC

New idea: anti-digest for EC?

Clear cell carcinomas benefit from IO therapy

De-escalation in ovarian cancer?